Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.
A new image morphometric method of nuclear grading is described and assessed in the context of the evaluation of histological samples from ductal carcinoma in situ of the breast and cervical intraepithelial neoplasia. The method results in a continuous scaled variable, or nuclear grading scale, expressed in SD units from measured normal nuclei from breast or cervix. For a given histological preinvasive neoplastic lesion, the mean nuclear grade of measured nuclei was shown to be analogous to the histopathological nuclear grade of the same lesion assigned subjectively by the pathologist. In a chemoprevention trial of the effect of difluoromethylornithine given for 1 month to subjects with cervical intraepithelial neoplasia grade 3, pathologists could see no difference in 14 histological sections taken before and after difluoromethylornithine treatment. However, the image morphometric method detected a systematic effect of lowered mean nuclear grade and a decrease in the variability of nuclear grade expression. Twelve of 14 samples showed a lower posttreatment mean nuclear grade (P<0.05), and 13 of the 14 samples showed a decrease in the SD of their nuclear grade distributions (P<0.01). This study demonstrates the use of image morphometric nuclear grading in a chemoprevention setting. It may be very useful in supplementing the pathologist's histopathological grading by providing objective, quantitative assessments.
Bacus
J W
JW
Bacus Laboratories, Inc., Lombard, Illinois 60148, USA.
Boone
C W
CW
Bacus
J V
JV
Follen
M
M
Kelloff
G J
GJ
Kagan
V
V
Lippman
S M
SM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001706:Biopsy; D001943:Breast Neoplasms / Q000473:pathology*; D002278:Carcinoma in Situ / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000473:pathology*; D002467:Cell Nucleus / Q000473:pathology*; D004273:DNA, Neoplasm / Q000032:analysis*; D016002:Discriminant Analysis; D018450:Disease Progression; D016903:Drug Monitoring / Q000379:methods; D000518:Eflornithine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D019044:Image Cytometry / Q000379:methods*; D007091:Image Processing, Computer-Assisted / Q000379:methods*; D016014:Linear Models; D009367:Neoplasm Staging / Q000379:methods*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D002578:Uterine Cervical Dysplasia / Q000473:pathology* / Q000517:prevention & control*
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D000518:Eflornithine